NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.30 -0.40 (-2.72 %) (As of 12/18/2018 04:00 PM ET)Previous Close$14.70Today's Range$14.07 - $15.1652-Week Range$9.56 - $25.96Volume614,900 shsAverage Volume310,873 shsMarket Capitalization$664.67 millionP/E RatioN/ADividend YieldN/ABeta4.09 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York. Receive RCKT News and Ratings via Email Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT Previous Symbol CUSIPN/A Webwww.rocketpharma.com Phone646-440-9100 Debt Debt-to-Equity Ratio0.28 Current Ratio12.52 Quick Ratio12.52 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.02 per share Price / Book2.04 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-29,490,000.00 Net MarginsN/A Return on Equity-49.35% Return on Assets-35.47% Miscellaneous Employees20 Outstanding Shares43,380,000Market Cap$664.67 million OptionableOptionable Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals Inc (NASDAQ:RCKT) released its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.03. View Rocket Pharmaceuticals' Earnings History. When is Rocket Pharmaceuticals' next earnings date? Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Rocket Pharmaceuticals. What price target have analysts set for RCKT? 5 equities research analysts have issued twelve-month price objectives for Rocket Pharmaceuticals' stock. Their predictions range from $22.00 to $30.00. On average, they expect Rocket Pharmaceuticals' share price to reach $26.3333 in the next year. This suggests a possible upside of 84.1% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals. What is the consensus analysts' recommendation for Rocket Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals. What are Wall Street analysts saying about Rocket Pharmaceuticals stock? Here are some recent quotes from research analysts about Rocket Pharmaceuticals stock: 1. According to Zacks Investment Research, "Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. " (11/16/2018) 2. William Blair analysts commented, "Rocket Pharmaceuticals, Inc. We are initiating coverage of Outperform rating and $32 fair value estimate. Rocket is a multi-platform biotechnology company that is focused on developing irst-in-class gene thera pies for rare dis- eases. The company’s lead candidate, RP-L102, is an ex vivo lentiviral gene therapy being developed for the treatment of Fanconi anemia (FA), with three additional ex vivo lentivirus programs in earlier development for the treatment of leukocyte adhesion deiciency-I (LAD-I), pyruvate kinase deiciency (PKD) , and infantile malignant osteopetrosis (IMO). We also expect the company to disclose its in vivo adeno-associated virus (AAV) gene therapy indication by year end, as the company anticipates having up to four programs in the clinic (likely and data from two (likely FA, LAD-I) in 2019. Plat- form and Longer Follow-Up." (7/10/2018) Has Rocket Pharmaceuticals been receiving favorable news coverage? News stories about RCKT stock have been trending somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. Who are some of Rocket Pharmaceuticals' key competitors? Some companies that are related to Rocket Pharmaceuticals include Allakos (ALLK), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Endocyte (ECYT), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX) and Corcept Therapeutics (CORT). Who are Rocket Pharmaceuticals' key executives? Rocket Pharmaceuticals' management team includes the folowing people: Mr. Gaurav Shah, CEO, Pres & Director (Age 43)Mr. John C. Militello, Principal Financial & Accounting Officer and Controller (Age 45)Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, Chief Operating Officer & Head of Devel. (Age 39)Dr. Claudine Prowse Ph.D., Sr. VP Corp. Devel. & IROMr. Jonathan Schwartz, Chief Medical Officer (Age 54) Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.70%), FMR LLC (2.70%), Vanguard Group Inc. (2.41%), Vanguard Group Inc (2.22%), Morgan Stanley (1.78%) and Federated Investors Inc. PA (1.30%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Kinnari Patel and Naveen Yalamanchi. View Institutional Ownership Trends for Rocket Pharmaceuticals. Which institutional investors are selling Rocket Pharmaceuticals stock? RCKT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, Alliancebernstein L.P., Virtus ETF Advisers LLC, Credit Suisse AG, TIAA CREF Investment Management LLC, JPMorgan Chase & Co. and Monarch Partners Asset Management LLC. Company insiders that have sold Rocket Pharmaceuticals company stock in the last year include David P Southwell and Naveen Yalamanchi. View Insider Buying and Selling for Rocket Pharmaceuticals. Which institutional investors are buying Rocket Pharmaceuticals stock? RCKT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Federated Investors Inc. PA, Morgan Stanley, BlackRock Inc., AXA, Vanguard Group Inc, Vanguard Group Inc. and MetLife Investment Advisors LLC. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include David P Southwell and Kinnari Patel. View Insider Buying and Selling for Rocket Pharmaceuticals. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $14.30. How big of a company is Rocket Pharmaceuticals? Rocket Pharmaceuticals has a market capitalization of $664.67 million. Rocket Pharmaceuticals employs 20 workers across the globe. What is Rocket Pharmaceuticals' official website? The official website for Rocket Pharmaceuticals is http://www.rocketpharma.com. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected] MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 343MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock?